Mohammad Vaziri Shares Breakthrough Insights on Factor XI Inhibitors for Thrombosis Prevention and Safer Anticoagulation
Mohammad Vaziri, Thoracic Surgery Professional at IRAN University of Medical Sciences (IUMS), posted on LinkedIn:
”Key points
Factor XI (FXI) inhibitors aim to uncouple hemostasis from thrombosis, presenting a novel approach to anticoagulation, with a reduced risk of bleeding compared with that associated with traditional anticoagulant agents.
Several phase II studies indicate that FXI inhibitors decrease thrombotic complications dose-dependently, without corresponding increases in bleeding, suggesting a favourable safety profile.
FXI inhibitors showed non-inferiority and potential superiority to low-molecular-weight heparin for the prevention of venous thromboembolism in patients undergoing orthopaedic surgery, with minimal bleeding risks observed at therapeutic doses.
Milvexian and abelacimab are theoretically promising for reducing the risk of bleeding associated with thromboprophylaxis in patients with atrial fibrillation; phase III clinical trials of safety and efficacy are ongoing.
In phase II trials involving patients with non-cardioembolic ischaemic stroke, no significant benefit of FXI inhibitors was found in terms of the primary ischaemic end points, but future phase III trials might find benefits in selected patients with large-vessel atherosclerosis.
The ongoing LIBREXIA-ACS trial will assess the use of milvexian in 16,000 patients with recent acute coronary syndrome.”
Reaf the full article here.
Title: Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism
Authors: Davide Capodanno, John H. Alexander, M. Cecilia Bahit, John W. Eikelboom, C. Michael Gibson, Shaun G. Goodman, Vijay Kunadian, Gregory Y. H. Lip, Renato D. Lopes, Roxana Mehran, Shamir R. Mehta, Manesh R. Patel, Jonathan P. Piccini, Sunil V. Rao, Christian T. Ruff, P. Gabriel Steg, Jeffrey I. Weitz, Dominick J. Angiolillo
Stay updated with Hemostasis Today.
-
Feb 1, 2026, 13:32Shiny K. Kajal: A Series On Reaching the Diagnosis of Immune Thrombocytopenia
-
Feb 1, 2026, 13:26Mary Cushman: Association of Atrial Fibrillation with Risk of Incident Cognitive Impairment
-
Feb 1, 2026, 13:23Abdulrahman Katib: Extended Low-Dose DOAC May Reduce VTE Recurrence
-
Feb 1, 2026, 13:22Jeff June: The Stroke That Wasn’t New – Why ‘Cryptogenic’ Often Means Undetected
-
Feb 1, 2026, 13:11Panagiotis Doukas: Plasma Desmosine as a Biomarker of Increased Proteolytic Activity in the Aortic Wall
-
Feb 1, 2026, 12:54Pierpaolo Di Micco: Starting a New Era for Anticoagulant Treatments
-
Feb 1, 2026, 12:16Erwin Loh: Immunotherapy Reduces Plaque in Arteries of Mice
-
Feb 1, 2026, 12:06Ney Carter Borges: The Central Role of Endothelial Dysfunction in Cardiovascular Disease Progression
-
Feb 1, 2026, 12:05Causes of Anemia – A Quick Overview From Mahnoor Shah